Matinas BioPharma Holdings, Inc.

MTNB • Biotechnology

$0.18

▲ +0.00 (+0.55%)

Current price

EarningsLatest report: Jun 30, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$1.17M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Positive revenue growth · 466.8%Manageable debt level · 0.28Healthy liquidity · 2.79Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:40 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.18

Change0.55%

Shares Out6.41M

Market Cap$1.17M

Enterprise Value$410.93K

52W Range0.23 - 3.09

Beta1.75

P/E-0.16

P/B0.65

P/FCF-0.18

EV/EBITDA-0.06

EV/FCF-0.06

Price$0.18

Change0.55%

Shares Out6.41M

Market Cap$1.17M

Enterprise Value$410.93K

52W Range0.23 - 3.09

Beta1.75

P/E-0.16

P/B0.65

P/FCF-0.18

EV/EBITDA-0.06

EV/FCF-0.06

Earnings Yield-626.88%

FCF Yield-550.63%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.28

Current Ratio2.79

Quick Ratio2.79

Volume330.39K

Avg Volume5.23M

EPS Surprise1.02

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

95/100

Why this score▼

Positive revenue growth · 466.8%Manageable debt level · 0.28Healthy liquidity · 2.79Weak profitability

Analyst view

Analyst sentiment and price target

MTNB

Analyst sentiment

Based on 8 analyst votes · 2026-09-05

94/100

Bullish

Hold

Bearish

Company Overview

IPO: 7/21/2014

Industry: Biotechnology

P/B i: 0.65

Debt / Equity i: 0.28

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.28

Current Ratio: 2.79

Quick Ratio: 2.79

Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 2 high-volume insider sells detected

STERN ADAM K

Transaction: 07/10/2026

SELL

Change

-344,710

Price

$0.35

Filing

08/13/2026

Type

SELL

STERN ADAM K

Transaction: 07/10/2026

BUY

Change

+344,710

Price

$0.35

Filing

08/13/2026

Type

BUY

Sanitam Partners LLC

Transaction: 06/10/2026

SELL

Change

-4,798,636

Price

$0.64

Filing

08/13/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
STERN ADAM K	SELL	-344,710	$0.35	07/10/2026	08/13/2026
STERN ADAM K	BUY	+344,710	$0.35	07/10/2026	08/13/2026
Sanitam Partners LLC	SELL	-4,798,636	$0.64	06/10/2026	08/13/2026
Sanitam Partners LLC	SELL	-1,406	$0.59	06/10/2026	08/13/2026
STERN ADAM K	BUY	+92,100	$0.64	10/31/2025	08/13/2026
STERN ADAM K	SELL	-92,100	$0.64	10/31/2025	08/13/2026
STERN ADAM K	BUY	+265	$0.59	10/16/2025	08/13/2026
STERN ADAM K	BUY	+800,000	$0.64	10/16/2025	08/13/2026
Murphy Keith	BUY	+11,600	$0.59	04/30/2025	05/02/2025
Jabbour Jerome D	BUY	+70,100	$0.59	04/30/2025	05/02/2025
D An Evelyn	BUY	+11,600	$0.59	04/30/2025	05/02/2025
Smith Robin L	BUY	+11,600	$0.59	04/30/2025	05/02/2025
NEUGEBOREN EDWARD	BUY	+11,600	$0.59	04/30/2025	05/02/2025
Pembroke & Partners LLC	BUY	+492	$0.59	04/08/2025	04/10/2025
Pembroke & Partners LLC	BUY	+1,679,182	$0.64	04/08/2025	04/10/2025
EIDE ROBERT J	BUY	+492	$0.59	04/08/2025	04/10/2025
EIDE ROBERT J	BUY	+1,679,182	$0.64	04/08/2025	04/10/2025
Sanitam Partners LLC	BUY	+703	$0.59	04/08/2025	04/10/2025
Sanitam Partners LLC	BUY	+2,399,318	$0.64	04/08/2025	04/10/2025
STERN ADAM K	OTHER	+4,798,636	Not reported	02/13/2025	04/10/2025

About the Company

Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.

Source - link

Peers

ACXP ADIL ADXN BCLI CDIO HCWB IBO KTTA NRSN VYNE

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years.

GlobeNewsWire

Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals

Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization

GlobeNewsWire

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders' equity of $3.02 million and has had losses in the most recent five fiscal years ended December 31, 2025. As previously disclosed, the Company is also not in compliance with Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders' equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders' equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. Due to its non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide.

GlobeNewsWire

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

BEDMINSTER, N. J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $4.

Globe News Wire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-08	-1.3175	-0.3	1.0175
2026-03-31	-0.78	-0.3	0.48
2025-04-15	-0.78	-1.68	-0.9
2025-03-26	-0.78	-1.5	-0.72
2024-11-13	-1.05	-0.85	0.2
2024-08-14	-0.83333	-1	-0.16667
2024-05-09	-0.03	-1.5	-1.47
2024-03-27	-1.12503	-1.5	-0.37497
2023-11-08	-0.03	-1.5	-1.47
2023-08-09	-0.03	-1.5	-1.47
2023-05-10	-1.5	-1.5	0
2023-03-15	-1	-1	0